We invest in frontier neuro. We back founders building technologies that read, repair, and enhance the brain, and AI that learns from it.
What we invest in:
NeuroAIBrain data, connectomics, and foundation models. AI that learns from the brain, and AI that helps understand it.
Neurotech & BCIImplants, wearables and neural interfaces that read and write to the brain and nervous system.
Precision NeuroShifting from population-wide care to approaches built on each patient's profile.
New ModalitiesRNA, gene, cell therapies, and delivery technologies that transcend conventional small molecules.
Human AugmentationTechnologies that improve cognition, focus, mood, and sleep, and keep the brain healthy.
Platforms & TherapeuticsHorizontal platforms, AI-driven discovery, and novel compounds.
Digital HealthApps, wearables, and platforms that help patients treat, prevent, or manage disease.
NeurometabolismHow drugs, diet, exercise, and gut microbiota affect metabolism and health.
UnchartedBuilding something that doesn’t fit these categories? If it’s frontier, we want to hear from you.
Companies we back:
Aerska RNAi medicines to treat, delay, and prevent neurodegeneration. Visit website
Ancilia CRISPR for live biotherapeutics and bacterial products. Visit website
Beckley Psytech Short duration, rapid-acting psychedelics. Visit website (Acquired )
Bexson Biomedical Novel ketamine formulations for pain and mental health. Visit website
Bloom Science Microbiome therapeutics platform for neurological disease. Visit website
Bright Minds Next-generation psychedelics for brain and mental health. Visit website (IPO )
Delix Therapeutics Non-hallucinogenic versions of psychedelic compounds. Visit website
Freedom Biosciences Next generation psychedelic therapeutics. Visit website
Gilgamesh Pharmaceuticals Clinical-stage neuroscience biotech. Visit website (Acquired )
Humans Anonymous Anonymous audio spaces for mental health. Visit website
Imyoo Patient-centric immune biodiscovery platform. Visit website
Iris Medicine Small-binding RNA medicine for neurodegenerative diseases. Visit website
Jimini Health AI-assisted therapy tool for therapists. Visit website
Journey Clinical Empowering mental health professionals to offer psychedelic therapy. Visit website
Maya Health Data intelligence platform for psychedelic therapy. Visit website
Mindstate Design Labs Next-generation psychedelic-inspired medicines. Visit website
Motif Neurotech Minimally invasive bioelectronic solutions for the brain. Visit website
Neurode Non-invasive neurostimulation starting with ADHD. Visit website
Remepy Hybrid treatments combining traditional drugs with digital therapeutics. Visit website
Sanmai Transcranial focused ultrasound for mental health. Visit website
Sculpta Bio Programmable RNA splicing medicine for complex brain diseases. Visit website
Siggy AI psychiatrist. Visit website
Tactogen Drug development platform for gentler and safer entactogens. Visit website
Terran Drug discovery platform for CNS and mental health. Visit website
Tripp VR/AR platform for meditation and psychedelic-like experiences. Visit website
And in stealth: biohybrid BCIs, wearable neurotech, brain data for AI, polypharmacology, organelle models, neuroinflammation biologics, patient data for AI models, a neuron-protective modality, cancer behavioral health, and a mental health marketplace.
Who we are:
Matias Serebrinsky , General Partner & Co-Founder. Previously led NVIDIA's accelerator for AI startups, Inception North America, and co-founded CookUnity ($1B ARR). LinkedIn , X .
Greg Kubin , General Partner & Co-Founder. Previously co-founded HelloSponsor, a SaaS platform (AngelPad '15). Ex-Morgan Stanley, Viacom. LinkedIn , X .
Danny Carbonero PhD , Associate. Ex-Breakout Ventures. PhD in Computational Neuroscience and Biomedical Engineering, Boston University. LinkedIn .
Dina Burkitbayeva MBA/MS , Co-Founder. CEO, Freedom Biosciences.
Martina Galdos , Operations Lead.
Tim Gardner PhD , Venture Partner. Chair of Bioengineering, University of Oregon. Founding member of Neuralink.
Negin Mokhtari PhD , Venture Partner. Luma Group, ex-Bioluminescence and Genoa Ventures.
Advisors:
John Krystal MD, Chief of Psychiatry, Yale-New Haven.
Graham Pechenik JD, patent attorney.
Jacob Robinson PhD, CEO, Motif Neurotech. Professor, Electrical and Computer Engineering, Rice University.
Chrystal Mavros PhD, microbiology, Columbia University.
Alex Amen PhD, BridgeBio, Doudna lab.
Building at the frontier of neuro or looking to get involved as an investor? Write to hi@psymed.ventures .
X · LinkedIn · Podcast · Newsletter · Privacy